Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07544719

Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis

The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Geriatric Anesthesia Postop Adult ICU Patients

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must be 65 years of age or older (in the geriatric age group),
  • Admitted to the intensive care unit after elective or emergency surgery
  • Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
  • Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
  • Have provided informed consent from the patient or their legal representative.

Exclusion criteria

  • Patients under 65 years of age
  • Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
  • Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
  • Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
  • Terminally ill palliative patients
  • Patients who refuse informed consent.

Treatment and study plan

Primary outcomes

  1. Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality

    Time frame: Postoperative day 1

    In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.

Study contacts

Contact information is provided by the study sponsor or research team.

Ayşe Yılkınç Tekirdaş

CONTACT

[email protected]

+905395721741

Sponsors and collaborators

Lead sponsor

Malatya Egitim Ve Arastirma Hastanesi

Other Gov

Registry information

Official study title

Prognostic Value of Systemic Immun Inflamation Index in Geriatrik Patient Admitted to the ICU After Surgery: A Prospective Observational Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2026
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.